RLYB
Companies
NASDAQ
Rallybio Corporation
Health Care
$0.31
-$0.65 (-67.94%)
Price Chart
Overview
About RLYB
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
Market Cap
$61.3M
Volume
27.6K
Avg. Volume
50.4K
P/E Ratio
-0.27444446
Dividend Yield
0.00%
Employees
45.0
Company Information
Risk & Correlation Analysis
Market Correlation
0.63
Low Correlation
Volatility
High (0.84)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
Medium Sensitivity
GDP Growth
High Sensitivity
Liquidity
High Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
Medium Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, RLYB shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$61.3M
Volume27.6K
P/E Ratio-0.27
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 9, 2024Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025